An estimated 500,000 scientists in 80,000 research labs globally
could accelerate their research and drug development by using
Pressure BioScience's (OTCQB: PBIO) innovative sample preparation
technology
This massive market represents a multi-billion-dollar
opportunity for PBIO and a chance for its investors to earn
significant returns.
"Cancer Moonshot" Initiative
In 2012, there were approximately 14.1 million new cancer cases
and 8.2 million deaths attributed to cancer globally. In total,
there are more than 100 types of cancer that affect humans.
As more people live to older age and lifestyles in the
developing world change, the rates of cancer continue to
increase.
The efforts to battle cancer received a big boost when President
Obama announced the establishment of the "Cancer Moonshot"
initiative during his 2016 State of the Union address. Led by Vice
President Biden, the Cancer Moonshot program is tasked with
accelerating cancer research with the goal of delivering new
therapies to more patients and improving cancer prevention and
early detection.
PBIO is set to benefit from the Cancer Moonshot initiative.
PBIO Technology Mitigates Risk for Key
Study
In July, PBIO announced that its Barocycler 2320Extreme system,
using its proprietary Pressure Cycling Technology (PCT) platform,
will play an important role in a major cancer research study led by
ProCan, an Australian research group recently named a Moonshot
collaborator by the White House
When asked to comment on the importance of sample preparation
quality, Dr. Isabelle M. Gorrillot, Managing Director of Areon
Biosciences, said, "PBIO's PCT platform may substantially improve
research data reliability and efficacy expectations of drug
candidates, and in turn significantly mitigate investment risk in
their development."
"By revealing, releasing, and preserving molecular structures
that are otherwise likely compromised through current, aggressive
mechanical and biochemical treatment of cells in tissue samples,
PBIO's PCT platform may significantly increase the speed of
targeting and accuracy of drug design and subsequent potency and
efficacy data," continued Gorrillot.
Disruptive Technology Could Have
Significant Long-Term Impact
PBIO's technology represents a true paradigm shift in sample
preparation. Current sample preparation methods are mostly
mechanical and highly inadequate and have remained unchanged for
more than 30 years.
The disruptive potential of PBIO's platform has been recognized
by more than 100 publications and peer reviewed journals from top
scientists, validating the advantages of PCT technology.
The technology has been secured through 24 issued patents and
even more patents are pending.
To date, more than 275 PCT systems have been installed for more
than 160 customers around the globe. Marquee customers of PBIO's
platform include Amgen, Merck, Biogen, Harvard Medical School,
Stanford University, the U.S. FDA, Centers for Disease Control,
National Institutes of Health and many more.
Partnered with Global Leader
The potential for PBIO's reach into this massive market to
accelerate got a big boost earlier this year when the company
signed a two-year co-marketing agreement with SCIEX, a global
leader in mass spectrometry. PCT offers SCIEX a companion solution
to their mass spectrometry offerings that improves overall research
results.
PBIO's potential hasn't gone unnoticed. Earlier this year the
company completed a $5 million PIPE offering which was
over-subscribed, resulting in a total of $6.3 million in new
funding for the company.
Record Revenue in Q3
Investors have more than just future promises to get them
excited. PBIO announced record revenue of $500,949 for the third
quarter. Record revenue was driven by growth in instrument sales,
which were up double-digits year-over-year.
The company is also expected to re-list on NASDAQ in the
near-term, which should further increase its visibility on Wall
Street, leading to a higher share price and improved valuation.
Bottom line, this is a stock you should have in your portfolio.
And you should own it before the Street catches wind of its
potential.
Learn more about PBIO by visiting their stock page at http://www.redchip.com/company/home/pbio/340/pbio and
watch our exclusive interview with CEO Richard
Schumacher.